文献速递消化系统肿瘤

美国女性下消化道内镜起始年龄与结直肠癌风险

Age at Initiation of Lower Gastrointestinal Endoscopy and Colorectal Cancer Risk Among US Women.
PubMed 文献 · JAMA Oncol · 2022-01-01

该前瞻性队列研究纳入111 801名美国女性健康专业人员,随访26年,评估不同年龄起始内镜筛查与结直肠癌风险的关系。与未接受内镜相比,45岁前起始内镜与结直肠癌风险降低相关(HR 0.37),45-49岁起始亦相关(HR 0.43)。45-49岁起始较50-54岁起始至60岁的结直肠癌累积发病率绝对降低为每10万人72例。

要点

  • 与未接受内镜相比,45岁前起始内镜与结直肠癌风险降低相关(HR 0.37;95%CI 0.26-0.53)。
  • 45-49岁起始内镜亦与结直肠癌风险降低相关(HR 0.43;95%CI 0.29-0.62)。
  • 45-49岁起始较50-54岁起始至60岁累积发病率绝对降低每10万人72例。

核心结论

  • 与未接受内镜相比,50岁前起始内镜与结直肠癌风险降低相关,包括55岁前诊断的结直肠癌。
  • 与50岁或之后起始筛查相比,50岁前起始筛查与更大的结直肠癌风险绝对降低相关。

研究设计与样本

  • 前瞻性队列研究,使用护士健康研究II(Nurses' Health Study II)数据,纳入1991年至2017年随访的美国女性健康专业人员。
  • 纳入111 801名入组时年龄26至46岁(中位36岁)的女性,随访26年,共2 509 358人年,记录519例结直肠癌。
  • 数据分析于2020年8月至2021年6月进行。

主要发现

  • 与未接受内镜相比,起始年龄<45岁组结直肠癌风险HR 0.37(95%CI 0.26-0.53),45-49岁组HR 0.43(95%CI 0.29-0.62),50-54岁组HR 0.47(95%CI 0.35-0.62),≥55岁组HR 0.46(95%CI 0.30-0.69)。
  • 45-49岁起始内镜较50-54岁起始,至60岁结直肠癌累积发病率绝对降低为每10万人72例。
  • 与未接受内镜相比,50岁前起始内镜与55岁前诊断的结直肠癌风险降低相关(<45岁:HR 0.45;95%CI 0.29-0.70;45-49岁:HR 0.43;95%CI 0.24-0.76)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In the past 4 years, the American Cancer Society and the US Preventive Services Task Force updated recommendations to initiate colorectal cancer (CRC) screening at 45 years of age to address the increasing incidence of CRC among adults younger than 50 years. However, empirical evidence evaluating the potential benefits of screening in younger populations is scant. OBJECTIVE: To examine the association between endoscopy initiation at different ages and risk of CRC among US women. DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study used data from the Nurses' Health Study II, which included US female health professionals followed up from 1991 through 2017. Data analysis was performed from August 2020 to June 2021. EXPOSURE: Age at initiation of sigmoidoscopy or colonoscopy for screening (routine screening or because of family history) or symptoms. MAIN OUTCOMES AND MEASURES: Incident CRC, confirmed by medical records, pathology reports, and the National Death Index. Cumulative incidence of CRC in each group was estimated with age as the time scale, and the absolute risk reduction associated with endoscopy initiation at different ages through 60 years was calculated. Cox proportional hazards regression was used to calculate hazard ratios (HRs) and 95% CIs, stratified by age and calendar year of questionnaire cycle and adjusted for CRC risk factors in the multivariable models. RESULTS: Among 111 801 women aged 26 to 46 years (median, 36 years) at enrollment, 519 incident CRC cases were documented over 26 years, encompassing 2 509 358 person-years of follow-up. In the multivariable analysis, compared with no endoscopy, undergoing endoscopy was associated with a significantly lower risk of incident CRC for age at initiation before 45 years (HR, 0.37; 95% CI, 0.26-0.53), 45 to 49 years (HR, 0.43; 95% CI, 0.29-0.62), 50 to 54 years (HR, 0.47; 95% CI, 0.35-0.62), and 55 years or older (HR, 0.46; 95% CI, 0.30-0.69). The absolute reduction in the estimated cumulative incidence of CRC through 60 years of age was 72 per 100 000 persons for initiation of endoscopy at 45 to 49 years of age vs 50 to 54 years of age. Compared with no endoscopy, initiation of endoscopy before 50 years of age was also associated with a reduced risk of CRC diagnosed before 55 years of age (<45 years: HR, 0.45 [95% CI, 0.29-0.70]; 45-49 years: HR, 0.43 [95% CI, 0.24-0.76]). CONCLUSIONS AND RELEVANCE: In this cohort study, compared with no endoscopy, initiation of endoscopy before 50 years of age was associated with a reduced risk of CRC, including CRC diagnosed before 55 years of age. Screening before 50 years of age was associated with greater absolute reduction in CRC risk compared with initiation of CRC screening at 50 years of age or later.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Ma W, Wang M, Wang K, et al. Age at Initiation of Lower Gastrointestinal Endoscopy and Colorectal Cancer Risk Among US Women. JAMA Oncol. 2022. PMID: 35511155. doi:10.1001/jamaoncol.2022.0883

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。